Medtronic (NYSE:MDT) wants the judge in its off-label marketing case against its neurovascular subsidiary ev3 to accept the sentence that the company and U.S. Justice Department have agreed upon.
Medtronic agreed in December 2018 to plead guilty to a misdemeanor charge related to its marketing of the Onyx Liquid Embolic System, pay $17.9 million and adopt new compliance and reporting terms for three years. Fridley, Minn.-based medtech giant Medtronic acquired ev3 when it picked up Covidien in 2015.